India's Biocon sees oral insulin partner by March

Wed Nov 23, 2011 3:11pm IST

Stocks

   

(For other news from the Reuters India Investment Summit, click here)

BANGALORE Nov 23 (Reuters) - Biocon Ltd, India's largest listed biotechnology company, expects to find a deep-pocketed global partner for its experimental oral insulin pill by end-March, its top executive said on Wednesday .

"We are in advanced discussions with potential partners," Biocon's Managing Director Kiran Mazumdar-Shaw told the Reuters India Investment Summit in Bangalore.

In January, Biocon had said it was looking for a partner after its oral insulin, IN-105, failed to meet the main goal of an Indian late-stage trial in patients with type-2 diabetes.

Mazumdar-Shaw, however, declined to name any potential partners.

She also said the planned IPO of its contract research organisation, Syngene, was on track.

(For summit blog: blogs.reuters.com/summits/)

(For more on the Reuters India Investment Summit, see ) (Reporting by Anand Basu, Jochelle Mendonca and Aftab Ahmed in Bangalore. Editing by Sriraj Kalluvila, Saumyadeb Chakrabarty)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Telecom Sector

REUTERS SHOWCASE

Election 2014

Election 2014

Breakingviews: Singh wasn’t king, Modi could be  Full Article 

Quarterly Results

Quarterly Results

Ambuja net profit up 6.6 percent, expects recovery after elections  Full Article 

Conspiracy Lawsuit

Conspiracy Lawsuit

Apple, Google agree to pay over $300 million   Full Article 

Stock Split Trend

Stock Split Trend

Trend-setter Apple's stock split could bring out the copycats  Full Article 

Winning Start

Winning Start

Microsoft beats Wall Street on new CEO debut   Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage